Overview

Incretin Effect and Use After Clinical Islet Transplantation

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
We aim to study if the administration of medications to increase the secretion of hormones from the intestines can improve glycemic control, reduce insulin use and promote β-cell regeneration/expansion in subjects with type 1 diabetes following islet transplantation who are back using small doses of insulin because of early graft dysfunction. We believe that the results will enable us to understand whether these drugs could be useful in islet transplant recipients, particularly if glycemic control deteriorates.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alberta
Collaborator:
Juvenile Diabetes Research Foundation
Treatments:
Pantoprazole
Sitagliptin Phosphate